image
Healthcare - Biotechnology - NASDAQ - US
$ 2.6
4 %
$ 358 M
Market Cap
-7.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one CMPX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.6 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one CMPX stock under the base case scenario is HIDDEN Compared to the current market price of 2.6 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one CMPX stock under the best case scenario is HIDDEN Compared to the current market price of 2.6 USD, Compass Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-50.4 M OPERATING INCOME
-20.91%
-42.5 M NET INCOME
-8.33%
-40.6 M OPERATING CASH FLOW
-19.03%
27 M INVESTING CASH FLOW
117.83%
2.94 M FINANCING CASH FLOW
-96.13%
0 REVENUE
0.00%
-12.2 M OPERATING INCOME
18.65%
-10.5 M NET INCOME
19.86%
-11.1 M OPERATING CASH FLOW
-2.76%
29 M INVESTING CASH FLOW
347.60%
-2 K FINANCING CASH FLOW
-200.00%
Balance Sheet Compass Therapeutics, Inc.
image
Current Assets 154 M
Cash & Short-Term Investments 152 M
Receivables 0
Other Current Assets 1.42 M
Non-Current Assets 2.99 M
Long-Term Investments 0
PP&E 2.67 M
Other Non-Current Assets 320 K
Current Liabilities 7.8 M
Accounts Payable 4.09 M
Short-Term Debt 1.2 M
Other Current Liabilities 2.51 M
Non-Current Liabilities 536 K
Long-Term Debt 536 K
Other Non-Current Liabilities -1
EFFICIENCY
Earnings Waterfall Compass Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 1.89 M
Gross Profit -1.89 M
Operating Expenses 48.5 M
Operating Income -50.4 M
Other Expenses -7.87 M
Net Income -42.5 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-28.61% ROE
-28.61%
-27.09% ROA
-27.09%
-33.51% ROIC
-33.51%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Compass Therapeutics, Inc.
image
Net Income -42.5 M
Depreciation & Amortization 1.89 M
Capital Expenditures -30 K
Stock-Based Compensation 6.12 M
Change in Working Capital -2.91 M
Others 2.35 M
Free Cash Flow -40.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Compass Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CMPX of $5 , with forecasts ranging from a low of $5 to a high of $5 .
CMPX Lowest Price Target Wall Street Target
5 USD 92.31%
CMPX Average Price Target Wall Street Target
5 USD 92.31%
CMPX Highest Price Target Wall Street Target
5 USD 92.31%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Compass Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Mar 10, 2023
Bought 33.7 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 10000
3.37 USD
1 year ago
Feb 27, 2023
Bought 79.6 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
3.98 USD
1 year ago
Feb 15, 2023
Bought 77.2 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
3.86 USD
1 year ago
Jan 31, 2023
Bought 81 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
4.05 USD
1 year ago
Jan 24, 2023
Bought 83.8 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
4.19 USD
2 years ago
Nov 22, 2022
Sell 62.6 K USD
Bisker-Leib Vered
Chief Operating Officer
- 14929
4.19 USD
2 years ago
Nov 23, 2022
Sell 41.1 K USD
Bisker-Leib Vered
Chief Operating Officer
- 9569
4.3 USD
2 years ago
Nov 25, 2022
Sell 8.72 USD
Bisker-Leib Vered
Chief Operating Officer
- 2
4.36 USD
2 years ago
Nov 08, 2022
Bought 1.29 M USD
ORBIMED ADVISORS LLC
Director
+ 402000
3.21 USD
2 years ago
Nov 08, 2022
Bought 1.29 M USD
GORDON CARL L
Director
+ 402000
3.21 USD
2 years ago
Sep 07, 2022
Bought 45.4 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 15000
3.03 USD
2 years ago
Sep 01, 2022
Bought 42.4 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 15000
2.83 USD
2 years ago
Aug 17, 2022
Bought 45.8 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 15000
3.05 USD
2 years ago
Aug 10, 2022
Bought 39.6 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 15000
2.64 USD
2 years ago
Aug 01, 2022
Bought 38.7 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 15000
2.58 USD
2 years ago
Jun 21, 2022
Bought 56 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
2.8 USD
2 years ago
Jun 16, 2022
Bought 46.8 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
2.34 USD
2 years ago
Jun 13, 2022
Bought 68.7 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 30000
2.29 USD
2 years ago
Jun 06, 2022
Bought 84.9 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 30000
2.83 USD
2 years ago
Jun 01, 2022
Bought 60.6 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
3.03 USD
2 years ago
May 26, 2022
Bought 60.8 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20000
3.04 USD
2 years ago
May 23, 2022
Bought 49.9 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 18355
2.72 USD
2 years ago
May 17, 2022
Bought 49.9 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 20215
2.47 USD
2 years ago
May 11, 2022
Bought 76.5 K USD
GORDON CARL L
director:
+ 30722
2.49 USD
2 years ago
May 12, 2022
Bought 228 K USD
GORDON CARL L
director, 10 percent owner:
+ 97094
2.35 USD
2 years ago
May 11, 2022
Bought 116 K USD
GORDON CARL L
director, 10 percent owner:
+ 64700
1.79 USD
2 years ago
May 13, 2022
Bought 76.5 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 30722
2.49 USD
2 years ago
May 12, 2022
Bought 228 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 97094
2.35 USD
2 years ago
May 11, 2022
Bought 116 K USD
OrbiMed Genesis GP LLC
director:
+ 64700
1.79 USD
2 years ago
May 11, 2022
Bought 116 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 64700
1.79 USD
2 years ago
May 06, 2022
Bought 39.1 K USD
OrbiMed Genesis GP LLC
director:
+ 24447
1.6 USD
2 years ago
May 10, 2022
Bought 39.1 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 24447
1.6 USD
2 years ago
May 09, 2022
Bought 142 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 90712
1.56 USD
2 years ago
May 06, 2022
Bought 16.6 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 10200
1.63 USD
2 years ago
May 06, 2022
Bought 39.1 K USD
GORDON CARL L
director:
+ 24447
1.6 USD
2 years ago
May 09, 2022
Bought 142 K USD
GORDON CARL L
director, 10 percent owner:
+ 90712
1.56 USD
2 years ago
May 06, 2022
Bought 16.6 K USD
GORDON CARL L
director, 10 percent owner:
+ 10200
1.63 USD
2 years ago
May 10, 2022
Bought 50.1 K USD
Schuetz Thomas J.
CHIEF EXECUTIVE OFFICER
+ 27836
1.8 USD
3 years ago
Nov 04, 2021
Bought 6.25 M USD
GORDON CARL L
director, 10 percent owner:
+ 1785715
3.5 USD
3 years ago
Nov 04, 2021
Bought 12.5 M USD
GORDON CARL L
director, 10 percent owner:
+ 3571428
3.5 USD
3 years ago
Nov 04, 2021
Bought 6.25 M USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 1785715
3.5 USD
3 years ago
Nov 04, 2021
Bought 12.5 M USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 3571428
3.5 USD
4 years ago
Jun 19, 2020
Bought 1.45 M USD
Sunderland Julie
Director
+ 289118
5 USD
4 years ago
Jun 19, 2020
Bought 487 K USD
Schuetz Thomas J.
Chief Executive Officer
+ 97431
5 USD
4 years ago
Jun 19, 2020
Bought 320 K USD
Ferneau Philip
Director
+ 64066
5 USD
4 years ago
Jun 19, 2020
Bought 1.25 M USD
Ferneau Philip
Director
+ 250000
5 USD
4 years ago
Jun 19, 2020
Bought 7.28 M USD
GORDON CARL L
director, 10 percent owner:
+ 1455132
5 USD
4 years ago
Jun 19, 2020
Bought 7.28 M USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 1455132
5 USD
19 years ago
May 12, 2005
Bought 7.16 K USD
GLADNEY DAN W
President and CEO
+ 1864
3.84 USD
19 years ago
May 11, 2005
Bought 11.6 K USD
GLADNEY DAN W
President and CEO
+ 3136
3.7 USD
19 years ago
May 10, 2005
Bought 13.9 K USD
YOUNGSTROM SCOTT P
CFO & VP of Finance
+ 4000
3.48 USD
20 years ago
Nov 15, 2004
Bought 9.8 K USD
SMITH JACK A
Director
+ 2000
4.9 USD
7. News
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year? Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year. zacks.com - 1 month ago
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. globenewswire.com - 1 month ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors. seekingalpha.com - 1 month ago
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024. globenewswire.com - 1 month ago
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX) Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 1 month ago
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago
Compass Therapeutics to Participate in Upcoming Investor Events BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024. globenewswire.com - 2 months ago
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2024 financial results and provided a business update. globenewswire.com - 2 months ago
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX. globenewswire.com - 2 months ago
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. globenewswire.com - 3 months ago
Compass Therapeutics to Participate in Upcoming Investor Events BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. globenewswire.com - 4 months ago
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. globenewswire.com - 5 months ago
8. Profile Summary

Compass Therapeutics, Inc. CMPX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 358 M
Dividend Yield 0.00%
Description Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Contact 80 Guest Street, Boston, MA, 02135 https://www.compasstherapeutics.com
IPO Date April 5, 2021
Employees 32
Officers Mr. Jonathan Anderman J.D. Vice President, Head of Legal & Corporate Secretary Ms. Vered Bisker-Leib MBA, Ph.D. Advisor Mr. Barry Shin J.D. Chief Financial Officer Dr. Thomas J. Schuetz M.D., Ph.D. Chief Executive Officer Dr. James Kranz Ph.D. Vice President and Head of Chemistry Manufacturing & Controls Anna Gifford Communications Manager Dr. Minori Rosales M.D., Ph.D. Senior Vice President & Head of Clinical Development Ms. Karin Herrera B.A. Vice President & Head of Clinical Operations